Compare Bristol-Myers Squibb Co (BMY) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Philip Morris International Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.71 (market cap $129.94B), while Philip Morris International Inc. trades at $186.34 (market cap $290.24B). The key difference: Philip Morris International Inc. is far larger — about 2.2× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | PM | |
|---|---|---|
Market Cap | $129.94B | $290.24B |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $200.17 |
52-Week Low | $42.60 | $144.33 |
Enterprise Value | $163.92B | $333.36B |
Dividend Yield | 3.96% | 3.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Philip Morris International (PM) trades at $186.00, down 1.88% on the day, with a neutral technical signal. The stock shows strong profitability with a 25.56% net income margin and has beaten earnings estimates in two of the last three quarters. Recent news highlights a $500 million impairment charge and a lowered profit forecast due to cost pressures, though the IQOS brand was recognized as a top global brand. Analyst consensus remains bullish with a $211.17 price target.
The outlook is mixed; strong cash flow and brand strength support long-term value, but near-term headwinds from cost inflation and illicit market growth pose risks. The current valuation at a P/E of 25.57 appears fair given earnings resilience, making PM a hold for investors tolerant of sector-specific volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
